The Network aims for timely enrollment of diverse patients to its protocols. For each study, the Network develops a customized enrollment plan considering projected accrual rates from Core and Affiliate Centers, data on potentially eligible patients from the Center for International Blood and Marrow Transplant Research (CIBMTR) Database, potential enrollment barriers, competing studies, and other factors. The Network carefully monitors enrollment milestones and, if accrual to a study lags, the BMT CTN intervenes quickly to identify and resolve barriers to enrollment. In 2021, the Network adopted a policy of including a specific plan in each protocol for facilitating the participation of individuals from under-represented groups to enhance access to the trial.
Because of its large network, the BMT CTN can provide definitive answers to questions requiring large trials and can study rare diseases. It has completed studies in aplastic anemia, hemophagocytic lymphohistiocytosis, and sickle cell disease. The Network conducted the largest study of unrelated donor transplantation ever performed and the first and second-largest studies of hematopoietic cell transplantation for multiple myeloma ever conducted in the US. Most studies have accrued on their originally projected timeline.
For a list of currently enrolling studies, please navigate to the BMT CTN Studies Page.